Provided by Tiger Fintech (Singapore) Pte. Ltd.

Enveric Biosciences

1.31
-0.0400-2.96%
Post-market: 1.29-0.0183-1.40%19:10 EDT
Volume:61.47K
Turnover:81.84K
Market Cap:3.24M
PE:-0.12
High:1.36
Open:1.35
Low:1.31
Close:1.35
Loading ...

Enveric Biosciences Reveals New Data Expanding Clinical Potential of Lead Candidate EB-003 for CNS Disorders

Reuters
·
24 Jun

Enveric Biosciences Announces Data That Broadens Scope of Clinical Indication Potential for Lead Candidate Eb-003

THOMSON REUTERS
·
24 Jun

Enveric Biosciences to Participate in BIO International Convention

Reuters
·
16 Jun

Enveric Biosciences Inc: Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

THOMSON REUTERS
·
10 Jun

Enveric Biosciences Secures Notice of Allowance for Innovative Non-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

Reuters
·
10 Jun

Enveric Biosciences Inc. Conducted Annual Stockholders Meeting

Reuters
·
04 Jun

Enveric Biosciences Secures U.S. Patent for Novel Melatonin Receptor-Targeting Compounds, Boosting Sleep and CNS Therapeutics Potential

Reuters
·
03 Jun

BRIEF-Enveric Biosciences Reports Positive Preclinical Results For Lead Drug Candidate EB-003

Reuters
·
28 May

Enveric Biosciences announces results from EB-003 trial

TIPRANKS
·
28 May

Enveric Biosciences Announces Positive Preclinical Results for Depression Drug Candidate EB-003

Reuters
·
28 May

Enveric Biosciences Inc - Significant Improvements in Severe Chronic Depression Model

THOMSON REUTERS
·
28 May

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate Eb-003

THOMSON REUTERS
·
28 May

Enveric Biosciences Inc - Support for Safe Extended Daily Oral Administration

THOMSON REUTERS
·
28 May

Enveric Biosciences files new provisional patent application

TIPRANKS
·
20 May

Enveric Biosciences Announces New Provisional Patent Application for Promising Neuroplastogen Candidates Targeting Neurodegenerative Diseases

Reuters
·
20 May

BRIEF-Enveric Biosciences Q1 Net Income USD -2.2 Million

Reuters
·
15 May

Enveric Biosciences Q1 EPS $(1.22) Up From $(9.21) YoY

Benzinga
·
15 May

Enveric Biosciences Secures U.S. Patent for Innovative Mescaline Derivative Compounds in EVM401 Series

Reuters
·
15 May

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

THOMSON REUTERS
·
15 May

Press Release: Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

Dow Jones
·
15 May